Point72 Asset Management L.P. Lowers Holdings in LivaNova PLC (NASDAQ:LIVN)

Point72 Asset Management L.P. decreased its holdings in LivaNova PLC (NASDAQ:LIVN) by 50.5% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,036,248 shares of the company’s stock after selling 1,055,762 shares during the quarter. Point72 Asset Management L.P. owned approximately 1.91% of LivaNova worth $47,989,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Russell Investments Group Ltd. boosted its holdings in shares of LivaNova by 17.1% in the 4th quarter. Russell Investments Group Ltd. now owns 1,502 shares of the company’s stock valued at $70,000 after purchasing an additional 219 shares during the last quarter. Sterling Capital Management LLC boosted its holdings in shares of LivaNova by 800.6% in the 4th quarter. Sterling Capital Management LLC now owns 1,621 shares of the company’s stock valued at $75,000 after purchasing an additional 1,441 shares during the last quarter. Vestcor Inc acquired a new position in shares of LivaNova in the 4th quarter valued at $204,000. Optimize Financial Inc acquired a new position in shares of LivaNova in the 4th quarter valued at $208,000. Finally, Corton Capital Inc. purchased a new position in shares of LivaNova in the 4th quarter worth about $214,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

LivaNova Trading Up 0.6%

NASDAQ LIVN opened at $43.82 on Friday. The company’s fifty day simple moving average is $38.28 and its 200-day simple moving average is $44.96. LivaNova PLC has a 52 week low of $32.48 and a 52 week high of $63.57. The company has a current ratio of 3.37, a quick ratio of 2.87 and a debt-to-equity ratio of 0.46. The stock has a market cap of $2.39 billion, a P/E ratio of 104.33 and a beta of 0.84.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the company. Robert W. Baird raised their price objective on LivaNova from $55.00 to $61.00 and gave the stock an “outperform” rating in a report on Thursday, May 8th. Needham & Company LLC restated a “buy” rating and issued a $64.00 price objective on shares of LivaNova in a report on Tuesday. Wolfe Research lowered shares of LivaNova from an “outperform” rating to a “peer perform” rating in a research report on Wednesday, February 26th. Stifel Nicolaus dropped their price objective on shares of LivaNova from $72.00 to $60.00 and set a “buy” rating for the company in a research report on Wednesday, February 26th. Finally, Barclays dropped their price objective on shares of LivaNova from $56.00 to $55.00 and set an “equal weight” rating for the company in a research report on Thursday, May 8th. Two investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, LivaNova currently has an average rating of “Moderate Buy” and an average target price of $59.17.

LivaNova Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.